Inventor · disambiguated record
Michael S. Kinch
Also filed as: KINCH MICHAEL · KINCH MICHAEL S · KINCH MICHAEL SCOTT
19 granted patents·44 pending applications·185 citations·filing 2000–2023
94Inventor score
Files withKINCH MICHAEL S9MEDIMMUNE INC9PURDUE RESEARCH FOUNDATION8FUNCTIONAL GENETICS INC7MEDIMMUNE LLC5
Top patents by PatentIndex Score
63 records- 0195US7297337B2EphA2 T-cell epitopes and uses thereforMEDIMMUNE INC·Filed 2005·Granted Nov 20, 2007·26 cites·45 claims
- 0291US6927203B1Treatment of metastatic diseasePURDUE RESEARCH FOUNDATION·Filed 2000·Granted Aug 9, 2005·38 cites·46 claims
- 0390US8114407B2EphA2 T-cell epitopes and uses thereforSTORKUS WALTER J·Filed 2007·Granted Feb 14, 2012·12 cites·9 claims
- 0490US7101976B1EphA2 monoclonal antibodies and methods of making and using sameSMITHKLINE BEECHAM CORP·Filed 2001·Granted Sep 5, 2006·34 cites·21 claims
- 0589US7192698B1EphA2 as a diagnostic target for metastatic cancerPURDUE RESEARCH FOUNDATION·Filed 2000·Granted Mar 20, 2007·38 cites·64 claims
- 0687US2024101625A1Epha2 t-cell epitope agonists and uses thereforeUNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION·Filed 2023·Application pending·0 cites
- 0784US7776327B2EphA2 as a therapeutic target for cancerPURDUE RESEARCH FOUNDATION·Filed 2005·Granted Aug 17, 2010·3 cites·8 claims
- 0883US7402298B1EphA2 monoclonal antibodies and methods of making and using samePURDUE RESEARCH FOUNDATION·Filed 2004·Granted Jul 22, 2008·11 cites·9 claims
- 0981US7604799B2EphA4 AntibodiesMEDIMMUNE LLC·Filed 2004·Granted Oct 20, 2009·12 cites·9 claims
- 1078US7981410B2Therapeutic targeting of escort proteinsFUNCTIONAL GENETICS INC·Filed 2007·Granted Jul 19, 2011·3 cites·7 claims
- 1176US11787846B2EphA2 T-cell epitope agonists and uses thereforeUNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION·Filed 2020·Granted Oct 17, 2023·0 cites·22 claims
- 1276US10781240B2EPHA2 t-cell epitope agonists and uses thereforeUNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION·Filed 2018·Granted Sep 22, 2020·0 cites·18 claims
- 1376US7662770B2Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic targetPURDUE RESEARCH FOUNDATION·Filed 2003·Granted Feb 16, 2010·3 cites·15 claims
- 1473US8591887B2EPHA2 as a therapeutic target for cancerKINCH MICHAEL S·Filed 2010·Granted Nov 26, 2013·2 cites·6 claims
- 1572US8796423B2Anti-TSG101 antibodies and their uses for treatment of viral infectionsLI LIMIN·Filed 2008·Granted Aug 5, 2014·2 cites·2 claims
- 1671US7964708B2Anti-TSG101 antibodies and their uses for treatment of viral infectionsLI LIMIN·Filed 2007·Granted Jun 21, 2011·1 cites·8 claims
- 1770US9359402B2EphA2 T-cell epitope agonists and uses thereforeUNIV PITTSBURGH— OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION·Filed 2013·Granted Jun 7, 2016·0 cites·12 claims
- 1864US10131699B2EphA2 T-cell epitope agonists and uses thereforeUNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION·Filed 2016·Granted Nov 20, 2018·0 cites·6 claims
- 1963US2010143345A1Epha2 agonistic monoclonal antibodies and methods of use thereofMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 2063US2005147593A1EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disordersMEDIMMUNE INC·Filed 2004·Application pending·0 cites
- 2162US2005152899A1EphA2 agonistic monoclonal antibodies and methods of use thereofFiled 2004·Application pending·0 cites
- 2261US2010035925A1Compounds, pharmaceutical compositions an dmethods for inhibiting hiv infectivityFUNCTIONAL GENETICS INC·Filed 2009·Application pending·0 cites
- 2360US2005169931A1EphA2 as a therapeutic target for cancerPURDUE RESEARCH FOUNDATION·Filed 2005·Application pending·0 cites
- 2459US2010298545A1EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOFKINCH MICHAEL S·Filed 2009·Application pending·0 cites
- 2559US2010166657A1USE OF EphA4 AND MODULATOR OF EphA4 FOR DIAGNOSIS, TREATMENT AND PREVENTION OF CANCERMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 2659US2010260749A1Modulators of EphA2 and Ephrin-A1 for the treatment of fibrosis-related diseaseMEDIMMUNE INC·Filed 2008·Application pending·0 cites
- 2758US2004091486A1EphA2 agonistic monoclonal antibodies and methods of use thereofFiled 2003·Application pending·0 cites
- 2857US2007134254A1EphA2 agonistic monoclonal antibodies and methods of use thereofPURDUE RESEARCH FOUNDATION·Filed 2007·Application pending·0 cites
- 2957US2007166314A1EpA2 monoclonal antibodies and methods of use thereofMEDIMMUNE INC·Filed 2007·Application pending·0 cites
- 3056US2011053182A1Diagnosis of pre-cancerous conditions using pcdgf agentsKINCH MICHAEL S·Filed 2009·Application pending·0 cites
- 3155US2009162933A1Epha2 and hyperproliferative cell disordersKIENER PETER A·Filed 2008·Application pending·0 cites
- 3254US2005048550A1EphA2 T-cell epitope agonists and uses thereforUNIV PITTSBURGH·Filed 2004·Application pending·0 cites
- 3354US2007086943A1EphA2 agonistic monoclonal antibodies and methods of use thereofPURDUE RES FOUNDATION AND MEDI·Filed 2006·Application pending·0 cites
- 3454US2007161064A1Antibodies as a cancer diagnosticPURDUE RESEARCH FOUNDATION·Filed 2007·Application pending·0 cites
- 3554US2005153923A1Targeted drug delivery using EphA2 or EphA4 binding moietiesFiled 2004·Application pending·0 cites
- 3653US2009304721A1Toxin conjugated eph receptor antibodiesMEDLMMUNE INC·Filed 2006·Application pending·0 cites
- 3752US2006122138A1Modulators of EphA2 and EphrinA1 for the treatment of fibrosis-related diseaseMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 3851US2005281783A1Listeria-based EphA2 vaccinesKINCH MICHAEL S·Filed 2004·Application pending·0 cites
- 3951US2004028685A1EphA2 monoclonal antibodies and methods of use thereofFiled 2003·Application pending·0 cites
- 4050US2008089931A1EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disordersMEDIMMUNE INC·Filed 2007·Application pending·0 cites
- 4150US2012122112A1Antibodies as a cancer diagnosticKINCH MICHAEL S·Filed 2011·Application pending·0 cites
- 4250US2010286248A1Human fg01 gene and its applicationsFUNCTIONAL GENETICS INC·Filed 2009·Application pending·0 cites
- 4349US2005175616A1PCDGF receptor antibodies and methods of use thereofFiled 2004·Application pending·0 cites
- 4449US2005059592A1EphA2 and hyperproliferative cell disordersFiled 2004·Application pending·0 cites
- 4548US2007065887A1Diagnosis of pre-cancerous conditions using pcdgf agentsKINCH MICHAEL S·Filed 2004·Application pending·0 cites
- 4648US2011152343A1Protease inhibitors and broad-spectrum antiviralFUNCTIONAL GENETICS INC·Filed 2009·Application pending·0 cites
- 4747US2010278838A1Epha2 monoclonal antibodies and methods of use thereofMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 4847US2009220527A1Affinity optimized epha2 agonistic antibodies and methods of use thereofMEDIMMUNE LLC·Filed 2006·Application pending·0 cites
- 4946US2009285819A1Methods and compositions for treating influenzaFUNCTIONAL GENETICS INC·Filed 2007·Application pending·0 cites
- 5046US2005049176A1EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitutionFiled 2004·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Michael S. Kinch files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →